Back in 2006, the FDA launched an effort to force drug companies to win regulatory approval for medicines already on the market that actually were never approved. Numerous treatments had been available for years on a grandfathered basis because they predated stricter requirements.

But while the FDA program, called the Unapproved Drugs Initiative, succeeded in ensuring many older medicines are now safe and effective, it has come at a cost. Some companies decided to stop selling their drugs, leaving others with a monopoly that allowed them to charge sky-high prices. And a new analysis claims four such examples may be adding a combined $20.3 billion to U.S. health care spending.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy